Gastroenterology & Hepatology — MCQs
On this page
A 59-year-old man with decompensated cirrhosis due to hepatitis C is admitted with tense ascites and peripheral oedema. He undergoes large-volume paracentesis with removal of 6 litres of ascitic fluid. Which of the following is the most appropriate plasma expander to prevent post-paracentesis circulatory dysfunction?
A 64-year-old woman with primary sclerosing cholangitis and ulcerative colitis presents with a 2-month history of progressive pruritus, jaundice, and weight loss of 6 kg. Liver function tests show: bilirubin 156 μmol/L, ALT 98 U/L, ALP 645 U/L, albumin 32 g/L. CA19-9 is 420 U/mL (normal <37). MRCP shows a dominant stricture in the common hepatic duct. What is the most appropriate next step in management?
A 41-year-old man presents with a 4-month history of epigastric pain that is worse at night and between meals. The pain is partially relieved by food and antacids. He smokes 20 cigarettes per day. Upper GI endoscopy shows a 1.2 cm ulcer in the duodenal bulb with a clean base. Rapid urease test is negative. Biopsies from the antrum are negative for H. pylori on histology. What is the most appropriate next investigation?
A 56-year-old man presents with a 5-day history of severe epigastric pain, nausea, and vomiting. He drinks approximately 30 units of alcohol per week. On examination, he is tender in the epigastrium with voluntary guarding. Observations: pulse 102 bpm, BP 128/76 mmHg, temperature 37.8°C, oxygen saturation 94% on room air. Blood tests show: amylase 1420 U/L, CRP 185 mg/L, white cell count 14.2 × 10⁹/L, urea 8.4 mmol/L, calcium 2.08 mmol/L, glucose 11.3 mmol/L, LDH 420 U/L. Arterial blood gas shows: pH 7.32, PaO₂ 9.1 kPa, base excess -4.2. What is his modified Glasgow score for acute pancreatitis severity?
A 33-year-old woman with Crohn's disease affecting the terminal ileum and caecum has been on azathioprine 2 mg/kg for 6 months but continues to have active disease with frequent abdominal pain and diarrhoea. Colonoscopy shows deep ulceration at the ileocaecal valve. She is planning pregnancy in 6 months. What is the most appropriate next step in management?
A 50-year-old man with alcohol-related cirrhosis attends for an outpatient appointment. He has abstained from alcohol for 6 months. His liver is firm with a palpable spleen. Liver function tests show bilirubin 32 μmol/L, albumin 34 g/L, INR 1.4, and platelet count 98 × 10⁹/L. Upper GI endoscopy performed 18 months ago showed no varices. What is the most appropriate timing for repeat endoscopic variceal surveillance?
A 37-year-old woman presents with a 9-month history of abdominal discomfort, bloating, and alternating bowel habit. She opens her bowels 3-4 times daily with loose stools, alternating with periods of constipation. Symptoms improve after defecation. She has no rectal bleeding or weight loss. Blood tests including FBC, CRP, coeliac serology, and thyroid function are normal. What is the most appropriate diagnostic criterion to establish the diagnosis?
A 69-year-old man is admitted with haematemesis. He takes warfarin for atrial fibrillation. On arrival, his pulse is 118 bpm, BP 92/54 mmHg, and INR is 4.2. He has further haematemesis in the emergency department. What is the most appropriate immediate management of his coagulopathy?
A 26-year-old man with a 3-year history of ulcerative colitis affecting the entire colon presents for routine surveillance. He is currently in remission on mesalazine maintenance therapy. Colonoscopy shows no macroscopic evidence of active inflammation. Which of the following statements regarding his colorectal cancer surveillance is correct?
A 43-year-old woman presents with a 2-month history of epigastric pain and bloating. She reports that the pain is worse after eating fatty meals and is associated with belching. She has no alarm symptoms. Examination is unremarkable. What is the most appropriate initial management?
Gastroenterology & Hepatology UK Medical PG Practice Questions and MCQs
Question 51: A 59-year-old man with decompensated cirrhosis due to hepatitis C is admitted with tense ascites and peripheral oedema. He undergoes large-volume paracentesis with removal of 6 litres of ascitic fluid. Which of the following is the most appropriate plasma expander to prevent post-paracentesis circulatory dysfunction?
- A. Human albumin solution 20% at 8 g per litre of ascites removed (Correct Answer)
- B. Human albumin solution 20% at 6 g per litre of ascites removed
- C. Gelofusine 500 mL
- D. Normal saline 1000 mL
- E. No plasma expander is required
Explanation: ***Human albumin solution 20% at 8 g per litre of ascites removed***- For **large-volume paracentesis** (removal of >5 litres), guidelines recommend administering **human albumin solution (HAS)** at a dose of **8 g per litre** of fluid removed to prevent **Post-Paracentesis Circulatory Dysfunction (PPCD)**.- Albumin is the preferred plasma expander due to its superior **oncotic properties** and ability to restore **effective circulating volume**, thereby reducing the risk of **renal impairment** and other complications associated with PPCD.*Human albumin solution 20% at 6 g per litre of ascites removed*- While albumin is the correct choice, a dose of **6 g/L** is generally considered insufficient for paracentesis exceeding 5 liters, as the recommended dose for preventing **PPCD** is **8 g/L**.- Using a lower dose may lead to inadequate **intravascular volume** expansion and still predispose the patient to the complications of PPCD.*Gelofusine 500 mL*- **Synthetic colloids** like Gelofusine (a modified gelatin solution) are significantly **less effective** than albumin in preventing PPCD and have been linked to a higher incidence of **acute kidney injury** in cirrhotic patients.- A fixed volume of 500 mL is insufficient and does not correlate with the amount of fluid removed, making it an **inappropriate choice** for preventing PPCD after large-volume paracentesis.*Normal saline 1000 mL*- **Crystalloids** like normal saline are rapidly distributed to the **interstitial space** and are largely ineffective at maintaining sustained **intravascular volume** in patients with cirrhosis after large-volume paracentesis.- Administration of saline instead of albumin for large-volume paracentesis significantly increases the risk of **renal dysfunction** and rapid re-accumulation of ascites.*No plasma expander is required*- For any paracentesis involving the removal of **more than 5 litres** of ascitic fluid, plasma expansion with albumin is crucial to prevent **Post-Paracentesis Circulatory Dysfunction (PPCD)**.- Failing to administer a plasma expander in this scenario (6 litres removed) would likely lead to severe **hemodynamic instability**, **renal impairment**, and increased mortality.
Question 52: A 64-year-old woman with primary sclerosing cholangitis and ulcerative colitis presents with a 2-month history of progressive pruritus, jaundice, and weight loss of 6 kg. Liver function tests show: bilirubin 156 μmol/L, ALT 98 U/L, ALP 645 U/L, albumin 32 g/L. CA19-9 is 420 U/mL (normal <37). MRCP shows a dominant stricture in the common hepatic duct. What is the most appropriate next step in management?
- A. Perform ERCP with brush cytology and biliary stenting (Correct Answer)
- B. Commence prednisolone for possible IgG4-related cholangiopathy
- C. Commence high-dose ursodeoxycholic acid
- D. Arrange staging CT and refer for liver transplant assessment
- E. Perform percutaneous liver biopsy
Explanation: ***Perform ERCP with brush cytology and biliary stenting*** - The patient's history of **primary sclerosing cholangitis (PSC)** and **ulcerative colitis**, combined with **progressive pruritus, jaundice, weight loss**, a significantly elevated **CA19-9**, and a **dominant common hepatic duct stricture** on MRCP, are highly suggestive of **cholangiocarcinoma**. - **ERCP** is crucial for both diagnostic purposes (obtaining tissue via **brush cytology** from the stricture) and therapeutic intervention (relieving biliary obstruction with **stenting**) to manage symptoms and allow for further treatment planning. *Commence prednisolone for possible IgG4-related cholangiopathy* - While IgG4-related cholangiopathy can cause biliary strictures, the patient's strong history of **PSC** and **ulcerative colitis**, along with significant **malignancy red flags** (weight loss, very high CA19-9), make **cholangiocarcinoma** a far more pressing concern. - Steroid therapy is inappropriate before actively excluding malignancy through tissue sampling, and delaying specific diagnostic procedures could worsen the prognosis if it is indeed cancer. *Commence high-dose ursodeoxycholic acid* - High-dose **ursodeoxycholic acid (UDCA)** is not the appropriate first-line treatment for a patient presenting with acute obstructive jaundice and strong suspicion of **cholangiocarcinoma**. - UDCA primarily aims to slow the progression of PSC, but it does not resolve the acute biliary obstruction caused by a dominant stricture or address the potential malignancy. *Arrange staging CT and refer for liver transplant assessment* - While **cholangiocarcinoma** may necessitate a staging CT and potentially lead to discussions about **liver transplantation** (for early-stage perihilar tumors), these steps are premature before a definitive tissue diagnosis is established. - The immediate priority is to obtain a tissue diagnosis from the dominant stricture and relieve the biliary obstruction, which **ERCP** accomplishes. *Perform percutaneous liver biopsy* - A **percutaneous liver biopsy** is generally not the preferred method for diagnosing a **focal biliary stricture** or **cholangiocarcinoma** within the bile ducts. - Its diagnostic yield for strictures is low, and it carries risks, whereas **ERCP with brush cytology** directly accesses the stricture for better sampling and concurrent decompression.
Question 53: A 41-year-old man presents with a 4-month history of epigastric pain that is worse at night and between meals. The pain is partially relieved by food and antacids. He smokes 20 cigarettes per day. Upper GI endoscopy shows a 1.2 cm ulcer in the duodenal bulb with a clean base. Rapid urease test is negative. Biopsies from the antrum are negative for H. pylori on histology. What is the most appropriate next investigation?
- A. Fasting serum gastrin level (Correct Answer)
- B. CT abdomen and pelvis
- C. Repeat endoscopy in 6 weeks after proton pump inhibitor therapy
- D. Urea breath test for H. pylori
- E. Secretin stimulation test
Explanation: ***Fasting serum gastrin level*** - In a patient with a **H. pylori-negative**, NSAID-negative duodenal ulcer, a **fasting serum gastrin level** is the initial screening test for **Zollinger-Ellison Syndrome** (gastrinoma). - Gastrinoma should be suspected in cases of refractory ulcers, ulcers in distal locations, or severe peptic ulcer disease despite standard treatment. *CT abdomen and pelvis* - **Imaging studies** are used for **localization** of the tumor once a biochemical diagnosis of gastrinoma has been established. - CT scans have limited sensitivity for detecting small gastrinomas in the **duodenal wall**, which are better localized via endoscopic ultrasound. *Repeat endoscopy in 6 weeks after proton pump inhibitor therapy* - While follow-up endoscopy is essential for **gastric ulcers** to rule out malignancy, **duodenal ulcers** carry a very low risk of malignancy and rarely require repeat biopsy or follow-up if asymptomatic. - This step does not help investigate the **underlying etiology** of the H. pylori-negative ulceration. *Urea breath test for H. pylori* - This test would be redundant as both **Rapid Urease Test (RUT)** and **histology** from antral biopsies have already returned negative results. - While the urea breath test is highly accurate, it is not the next logical step after multiple direct invasive tests have already failed to show infection. *Secretin stimulation test* - This is a confirmatory test used if the **fasting serum gastrin** is equivocal (typically between 110–1000 pg/mL). - It is not the initial investigation of choice; gastrin levels must be measured first to determine if further provocative testing like the **secretin test** is warranted.
Question 54: A 56-year-old man presents with a 5-day history of severe epigastric pain, nausea, and vomiting. He drinks approximately 30 units of alcohol per week. On examination, he is tender in the epigastrium with voluntary guarding. Observations: pulse 102 bpm, BP 128/76 mmHg, temperature 37.8°C, oxygen saturation 94% on room air. Blood tests show: amylase 1420 U/L, CRP 185 mg/L, white cell count 14.2 × 10⁹/L, urea 8.4 mmol/L, calcium 2.08 mmol/L, glucose 11.3 mmol/L, LDH 420 U/L. Arterial blood gas shows: pH 7.32, PaO₂ 9.1 kPa, base excess -4.2. What is his modified Glasgow score for acute pancreatitis severity?
- A. 2
- B. 3
- C. 4 (Correct Answer)
- D. 5
- E. 6
Explanation: ***4*** - The **modified Glasgow score** includes **Age >55 years** (patient is 56 years) and **Glucose >10 mmol/L** (patient glucose is 11.3 mmol/L), contributing **two definite points**. - Additionally, the patient's **WCC of 14.2 × 10⁹/L** is close to the >15 threshold and the **PaO₂ of 9.1 kPa** is indicative of respiratory compromise, often considered to contribute to a higher score of **4** in the context of a severe acute pancreatitis presentation. *2* - This score would only account for the two clearly positive criteria (Age and Glucose), overlooking the **borderline derangements** in WCC and PaO₂. - A score of 2 generally indicates **mild pancreatitis**, which is inconsistent with the patient's severe epigastric pain, guarding, tachycardia, and significantly elevated **CRP (185 mg/L)**. *3* - While a score of 3 indicates **severe acute pancreatitis**, this option undervalues the combined clinical and biochemical severity, especially considering the elevated **CRP** and the borderline values of other Glasgow criteria. - A score of 3 would suggest that only one of the additional borderline criteria is considered positive, which doesn't fully capture the patient's systemic response. *5* - A score of 5 indicates a higher degree of **multi-organ dysfunction** than currently evident from the available strict criteria. - The patient's **urea (8.4 mmol/L)**, **calcium (2.08 mmol/L)**, and **LDH (420 U/L)** are not severe enough to meet the respective Glasgow thresholds for additional points to reach a score of 5. *6* - A score of 6 suggests **critical illness** with significant systemic complications, often requiring intensive care. - The current blood results, particularly **urea (8.4 mmol/L)**, **calcium (2.08 mmol/L)**, and **LDH (420 U/L)**, do not meet the criteria for such a high score based on the Glasgow scale.
Question 55: A 33-year-old woman with Crohn's disease affecting the terminal ileum and caecum has been on azathioprine 2 mg/kg for 6 months but continues to have active disease with frequent abdominal pain and diarrhoea. Colonoscopy shows deep ulceration at the ileocaecal valve. She is planning pregnancy in 6 months. What is the most appropriate next step in management?
- A. Commence infliximab and continue azathioprine (Correct Answer)
- B. Commence adalimumab and stop azathioprine
- C. Switch to methotrexate
- D. Add budesonide to current treatment
- E. Arrange for ileocaecal resection
Explanation: ***Commence infliximab and continue azathioprine***- **Combination therapy** with a **TNF inhibitor** (infliximab) and a **thiopurine** (azathioprine) is more effective than monotherapy for inducing and maintaining remission in active, refractory **Crohn's disease**, especially with **deep ulceration**.- Both medications are considered **safe during pregnancy**; maintaining remission before and during pregnancy is crucial for optimal maternal and fetal outcomes.*Commence adalimumab and stop azathioprine*- While **adalimumab** is an effective treatment, stopping **azathioprine** would result in monotherapy, which is generally less effective than combination therapy for patients with **deep ulceration** and active disease.- Continuing **azathioprine** alongside a **TNF inhibitor** helps reduce the risk of **immunogenicity** and the development of anti-drug antibodies against the biologic, improving long-term efficacy.*Switch to methotrexate*- **Methotrexate** is a potent **teratogen** and is absolutely **contraindicated in pregnancy** due to its high risk of fetal abnormalities and miscarriage.- It must be discontinued at least **3 to 6 months before conception**, making it an inappropriate choice for a patient planning pregnancy in 6 months.*Add budesonide to current treatment*- **Budesonide** is a locally acting corticosteroid used for **mild-to-moderate** ileocaecal disease, but it is insufficient for treating **deep ulceration** and severe inflammation.- It is not an effective **disease-modifying agent** for long-term maintenance or for achieving deep mucosal healing in severe cases.*Arrange for ileocaecal resection*- **Surgery** is typically reserved for complications like **strictures**, fistulae, or disease that is truly refractory to all medical therapies, or for acute complications like perforation.- In this case, the patient has active inflammation (deep ulceration) but has not yet failed **biologic therapy**, which should be attempted first before considering surgery.
Question 56: A 50-year-old man with alcohol-related cirrhosis attends for an outpatient appointment. He has abstained from alcohol for 6 months. His liver is firm with a palpable spleen. Liver function tests show bilirubin 32 μmol/L, albumin 34 g/L, INR 1.4, and platelet count 98 × 10⁹/L. Upper GI endoscopy performed 18 months ago showed no varices. What is the most appropriate timing for repeat endoscopic variceal surveillance?
- A. Repeat endoscopy in 3 years (Correct Answer)
- B. No further surveillance required as previous endoscopy was normal
- C. Repeat endoscopy in 6 months
- D. Repeat endoscopy in 1 year
- E. Repeat endoscopy in 2 years
Explanation: ***Repeat endoscopy in 3 years*** - According to **Baveno VI guidelines**, patients with **compensated cirrhosis** and no varices on initial screening should undergo repeat endoscopy every **2 to 3 years** if the underlying liver disease is managed or inactive (e.g., alcohol abstinence). - This patient has compensated disease despite **portal hypertension** (splenomegaly and thrombocytopenia), and since the previous endoscopy was normal, a 3-year interval is an appropriate surveillance choice. *No further surveillance required as previous endoscopy was normal* - Cirrhosis is a progressive condition, and **gastroesophageal varices** can develop over time as **portal venous pressure** increases. - Failure to monitor for varices puts the patient at risk for **life-threatening variceal hemorrhage**, a major cause of mortality in cirrhosis. *Repeat endoscopy in 6 months* - A 6-month interval is generally reserved for patients who have undergone **variceal band ligation** to ensure obliteration of varices. - It is unnecessarily frequent for a patient with **compensated cirrhosis** who showed no evidence of varices on an initial screen 18 months ago. *Repeat endoscopy in 1 year* - **Annual surveillance** is typically indicated if **small varices** were identified during the initial endoscopy or if the patient develops **liver decompensation**. - Since this patient's previous endoscopy was normal and he remains compensated, a 1-year interval is more frequent than required by current clinical standards. *Repeat endoscopy in 2 years* - While a 2-year interval is acceptable under some guidelines for **compensated cirrhosis**, the broader **Baveno consensus** allows for up to 3 years in patients with stable, inactive disease. - In the context of options where both 2 and 3 years might be considered, the 3-year mark represents the upper limit of the recommended window for those without varices or ongoing injury.
Question 57: A 37-year-old woman presents with a 9-month history of abdominal discomfort, bloating, and alternating bowel habit. She opens her bowels 3-4 times daily with loose stools, alternating with periods of constipation. Symptoms improve after defecation. She has no rectal bleeding or weight loss. Blood tests including FBC, CRP, coeliac serology, and thyroid function are normal. What is the most appropriate diagnostic criterion to establish the diagnosis?
- A. Symptoms present for at least 6 months with pain occurring at least 1 day per week in the last 3 months, related to defecation and associated with change in stool frequency or form (Correct Answer)
- B. Symptoms present for at least 3 months with pain occurring at least 3 days per month, related to defecation and associated with change in stool frequency or form
- C. Symptoms present for at least 12 months with pain occurring daily, associated with bloating and change in stool consistency
- D. Normal colonoscopy findings with biopsies excluding microscopic colitis
- E. Exclusion of organic disease with abdominal imaging and endoscopy
Explanation: ***Symptoms present for at least 6 months with pain occurring at least 1 day per week in the last 3 months, related to defecation and associated with change in stool frequency or form*** - This criterion accurately reflects the **Rome IV criteria** for diagnosing **Irritable Bowel Syndrome (IBS)**, requiring symptom onset at least **6 months** prior to diagnosis. - The core diagnostic elements are recurrent **abdominal pain** at least **1 day per week** in the last 3 months, related to **defecation**, or associated with a change in **stool frequency** or **form**. *Symptoms present for at least 3 months with pain occurring at least 3 days per month, related to defecation and associated with change in stool frequency or form* - This description aligns with the **Rome III criteria**, which is an older classification superseded by the more current Rome IV criteria. - The **Rome IV criteria** updated the frequency of pain from 3 days per month to at least **1 day per week** to enhance diagnostic specificity. *Symptoms present for at least 12 months with pain occurring daily, associated with bloating and change in stool consistency* - **Daily pain** is not a mandatory requirement for the diagnosis of IBS; patients typically experience intermittent pain rather than constant daily pain. - While **bloating** and change in **stool consistency** are common, the **12-month duration** and daily pain frequency do not precisely match the **Rome IV diagnostic criteria**. *Normal colonoscopy findings with biopsies excluding microscopic colitis* - IBS is a **positive clinical diagnosis** based on symptom criteria, not solely a diagnosis of exclusion requiring invasive procedures like colonoscopy. - For a 37-year-old with classic symptoms and no **alarm features** (e.g., weight loss, rectal bleeding, abnormal blood tests), colonoscopy is not routinely indicated for diagnosis. *Exclusion of organic disease with abdominal imaging and endoscopy* - While it's important to rule out significant organic disease, IBS is diagnosed by meeting specific **Rome IV symptom criteria**, not merely by excluding other conditions through extensive investigations. - Performing routine **abdominal imaging and endoscopy** in the absence of **alarm features** is not recommended and can lead to unnecessary costs and patient anxiety.
Question 58: A 69-year-old man is admitted with haematemesis. He takes warfarin for atrial fibrillation. On arrival, his pulse is 118 bpm, BP 92/54 mmHg, and INR is 4.2. He has further haematemesis in the emergency department. What is the most appropriate immediate management of his coagulopathy?
- A. Give prothrombin complex concentrate and intravenous vitamin K (Correct Answer)
- B. Give fresh frozen plasma alone
- C. Give oral vitamin K and withhold warfarin
- D. Give tranexamic acid intravenously
- E. Give cryoprecipitate
Explanation: ***Give prothrombin complex concentrate and intravenous vitamin K*** - This patient presents with **major life-threatening hemorrhage** (haematemesis with hypotension) while on warfarin, requiring immediate reversal of the **INR**. - **Prothrombin complex concentrate (PCC)** provides rapid reversal by supplying factors II, VII, IX, and X, while **intravenous vitamin K** ensures sustained clotting factor production after the PCC effects wear off. *Give fresh frozen plasma alone* - **Fresh frozen plasma (FFP)** requires a much larger volume and takes longer to administer and provide effective reversal compared to **PCC**. - According to guidelines, FFP is only recommended for warfarin reversal if **PCC** is unavailable or contraindicated due to fluid overload risk. *Give oral vitamin K and withhold warfarin* - **Oral vitamin K** is inappropriate here as it takes several hours to begin working and is reserved for patients with high INR but **no major bleeding**. - In the setting of **haemodynamic instability** and active bleeding, the clinical urgency mandates immediate intravenous reversal agents. *Give tranexamic acid intravenously* - While **tranexamic acid** is an antifibrinolytic used in various bleeding scenarios, it does not address the underlying **warfarin-induced coagulopathy**. - Management must prioritize replacing the **vitamin K-dependent clotting factors** that are deficient in this patient. *Give cryoprecipitate* - **Cryoprecipitate** is primarily used to replace **fibrinogen** in conditions like DIC or massive transfusion protocols with documented hypofibrinogenemia. - It does not contain sufficient quantities of the specific **clotting factors** (II, VII, IX, X) needed to reverse warfarin therapy effectively.
Question 59: A 26-year-old man with a 3-year history of ulcerative colitis affecting the entire colon presents for routine surveillance. He is currently in remission on mesalazine maintenance therapy. Colonoscopy shows no macroscopic evidence of active inflammation. Which of the following statements regarding his colorectal cancer surveillance is correct?
- A. Colonoscopic surveillance should commence 10 years after diagnosis
- B. Colonoscopic surveillance should be performed annually
- C. Chromoendoscopy with targeted biopsies is the preferred surveillance method (Correct Answer)
- D. Surveillance colonoscopy is not indicated as he is in remission
- E. Surveillance should only commence if dysplasia is detected
Explanation: ***Chromoendoscopy with targeted biopsies is the preferred surveillance method***- **Chromoendoscopy** involves applying dyes (like indigo carmine) to the colonic mucosa to enhance the detection of **dysplastic lesions**, which can be subtle in IBD patients.- International guidelines, including those from the **British Society of Gastroenterology (BSG)**, prefer this over random biopsies due to its significantly higher **diagnostic yield** for neoplasia.*Colonoscopic surveillance should commence 10 years after diagnosis*- For patients with **pancolitis** or left-sided colitis, surveillance typically begins **8 years after the onset of symptoms**, rather than 10 years after a clinical diagnosis.- Earlier screening is crucial because the risk of **colorectal adenocarcinoma** increases significantly after a decade of chronic inflammation.*Colonoscopic surveillance should be performed annually*- The frequency of surveillance is determined by **stratified risk factors** (low, intermediate, or high); it is not automatically annual for everyone.- While high-risk individuals (e.g., those with **Primary Sclerosing Cholangitis**) require annual checks, those at lower risk may only require surveillance every **3 to 5 years**.*Surveillance colonoscopy is not indicated as he is in remission*- Colorectal cancer risk in **Ulcerative Colitis** is primarily driven by the **extent of disease** and **duration of inflammation**, regardless of current clinical remission.- Surveillance is a preventive strategy meant for stable patients to detect **asymptomatic dysplasia** before it progresses to invasive cancer.*Surveillance should only commence if dysplasia is detected*- The fundamental purpose of initiating a surveillance program is the **early detection** of dysplasia in patients who are known to have a high baseline risk.- Waiting for dysplasia to be detected before starting surveillance is illogical, as **surveillance** is the very tool used to find it.
Question 60: A 43-year-old woman presents with a 2-month history of epigastric pain and bloating. She reports that the pain is worse after eating fatty meals and is associated with belching. She has no alarm symptoms. Examination is unremarkable. What is the most appropriate initial management?
- A. Trial of proton pump inhibitor therapy for 4 weeks
- B. Upper GI endoscopy
- C. Helicobacter pylori stool antigen test and eradication if positive (Correct Answer)
- D. Abdominal ultrasound scan
- E. Trial of a prokinetic agent such as metoclopramide
Explanation: ***Helicobacter pylori stool antigen test and eradication if positive*** - In patients under **55 years of age** presenting with **uninvestigated dyspepsia** and no **alarm symptoms**, the recommended first-line approach is the **'test and treat'** strategy for H. pylori. - Non-invasive testing via **stool antigen** or **urea breath test** is cost-effective and addresses the most common treatable cause of persistent epigastric pain. *Trial of proton pump inhibitor therapy for 4 weeks* - While **PPI therapy** is a management option, guidelines prioritize **H. pylori testing** first to prevent masking underlying infection or missing a definitive cure. - PPIs should generally be reserved for patients who test negative for **H. pylori** or as a secondary step after failed eradication. *Upper GI endoscopy* - This invasive procedure is not indicated unless the patient is **over 55 years** or presents with **alarm symptoms** like dysphagia, weight loss, or persistent vomiting. - Endoscopy is not cost-effective for **younger patients** with simple dyspepsia and an unremarkable physical examination. *Abdominal ultrasound scan* - Although fatty meals can trigger **biliary colic**, the primary symptoms of bloating and epigastric pain are more characteristic of **dyspepsia** or peptic ulcer disease. - Ultrasound is the investigation of choice if **gallstones** or cholecystitis are strongly suspected, but it is not the first-line test for generalized dyspeptic symptoms. *Trial of a prokinetic agent such as metoclopramide* - **Prokinetic agents** are typically used for **functional dyspepsia** with predominant bloating or gastroparesis, but they are not first-line for uninvestigated symptoms. - Their use is limited by side effects and they do not address the high prevalence of **H. pylori infection** in the population.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free